Jaypirca

(pirtobrutinib)

Uses, side effects, dosage information & price range

Eli Lilly Nederland B.V.

About this medicine

Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Brutons tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

IclusigComposition: ponatinibIncyte Biosciences Distribution B.V.

Price on RequestView Details →

ItovebiComposition: inavolisibRoche Registration GmbH

Price on RequestView Details →

LorviquaComposition: lorlatinibPfizer Europe MA EEIG

Price on RequestView Details →

StivargaComposition: regorafenibBayer Pharma AG

Price on RequestView Details →

Imatinib TevaComposition: imatinibTeva B.V.

Price on RequestView Details →

Key Information

Salt / Composition

pirtobrutinib